Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis
ConclusionsA clinical-genetic model including BMI and SNP FPGS 10101 was found to have a modest prediction ability for methotrexate intolerance.Key Points•Methotrexate intolerance (symptomatic adverse effects) was common and occurred in 37% patients over 6 months.•SNP FPGS rs10106 and low body mass index were associated with methotrexate intolerance.•Clinico-genetic model had a modest ability of 66% for predicting intolerance.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Anxiety | Arthritis | Genetics | Laboratory Medicine | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study